PyL Imaging Agent Accurately Detects Recurrent Prostate Cancer Lesions, Trial Shows

PyL Imaging Agent Accurately Detects Recurrent Prostate Cancer Lesions, Trial Shows
Progenics PharmaceuticalsPyL, a new imaging agent for positron emission tomography (PET) scans, can accurately detect the location of recurrent prostate cancer lesions, according to data from a Phase 3 clinical trial. “The positive results of our Phase 3 CONDOR trial reinforce our belief in the potential of PyL to enable better physician treatment decisions and, ultimately, improve patient outcomes,” David Mims, Progenics’ interim CEO, said in a press release. The company plans to submit a new drug application for PyL to the U.S. Food and Drug Administration in the second half of this year, according to Mims. “There is a need for improved diagnostics for prostate cancer to replace conventional imaging tests that have limited performance characteristics, especially in men with biochemical recurrence of their disease,” said Barry Siegel, MD, CONDOR’s principal investigator at the Mallinckrodt Institute of Radiology at Washington University School of Medicine clinical site. PyL (18F-DCFPyl) is a
Subscribe or to access all post and page content.